SKG0201 Injection for spinal muscular atrophies of childhood

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 28 Apr 2026: Trial registered, NCT07554924
  2. 15 Jul 2026: Trial started, NCT07554924

The trials

NCT07554924: A Phase I/II Clinical Study to Evaluate SKG0201 Injection in Subjects With Spinal Muscular Atrophy Type I

State
Under way
Phase
Phase 1 and Phase 2
People
11 planned
Started
15 Jul 2026
Primary completion
25 May 2029
Arms
Dose-escalation
Results
None posted
  1. 28 Apr 2026: Trial registered
  2. 15 Jul 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Kind of treatment: Gene therapy.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.